Novo Nordisk A/S – Share repurchase programme
May 25 2021 - 9:06AM
Novo Nordisk A/S – Share repurchase programme
Novo Nordisk A/S – Share repurchase
programme
Bagsværd, Denmark,
25 May 2021 – On
7 May 2021, Novo Nordisk initiated a share repurchase programme in
accordance with Article 5 of Regulation No 596/2014 of the European
Parliament and Council of 16 April 2014 (MAR) and the Commission
Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe
Harbour Rules"). This programme is part of the overall share
repurchase programme of up to DKK 18 billion to be executed during
a 12-month period beginning 3 February 2021.
Under the programme initiated 7 May 2021, Novo Nordisk will
repurchase B shares for an amount up to DKK 3.3 billion in the
period from 10 May 2021 to 3 August 2021.
Since the announcement as of 17 May 2021, the following
transactions have been made:
|
Number ofB shares |
Averagepurchase price |
Transactionvalue, DKK |
Accumulated, last announcement |
379,000 |
|
177,630,842 |
17 May
2021 |
124,000 |
487.27 |
60,421,529 |
18 May
2021 |
120,000 |
486.81 |
58,417,228 |
19 May
2021 |
120,000 |
485.57 |
58,268,322 |
20 May
2021 |
115,000 |
489.69 |
56,314,158 |
21 May
2021 |
115,000 |
494.62 |
56,881,693 |
Accumulated under the programme |
973,000 |
|
467,933,771 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of
12,176,275 B shares of DKK 0.20 as treasury shares, corresponding
to 0.5% of the share capital. The total amount of A and B shares in
the company is 2,310,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to
DKK 18 billion during a 12-month period beginning 3 February 2021.
As of 21 May 2021, Novo Nordisk has since 3 February 2021
repurchased a total of 13,337,777 B shares at an average share
price of DKK 453.92 per B share equal to a transaction value of DKK
6,054,293,021.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo
Nordisk employs about 45,800 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media: |
|
|
Mette Kruse
Danielsen |
+45 3079 3883 |
mkd@novonordisk.com |
Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Valdemar Borum
Svarrer |
+45 3079 0301 |
jvls@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
David Heiberg
Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
Mark Joseph Root
(US) |
+1 848 213
3219 |
mjhr@novonordisk.com |
Company announcement No. 35 / 2021
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024